Increased Risk for Malignancies in 131 Affected CTLA4 Mutation Carriers
David Egg(University of Freiburg), Bodo Grimbacher(University of Freiburg), Charlotte Schwab(University Medical Center Freiburg), Maximilian Seidl(University of Freiburg), Olaf Neth(Instituto de Biomedicina de Sevilla), Philippe Delvenne(University of Liège), Satoshi Okada(Rockefeller University), Klaus Warnatz(University of Freiburg), Peter D. Arkwright(University of Manchester), Michel Moutschen(University of Liège), Daniel Wolff(German Cancer Research Center), Ann‐Christin Pecher(University Children's Hospital Tübingen), Annemarie Gabrysch(University of Freiburg), Scott B. Snapper(Boston Children's Hospital), Catriona McLean(The Alfred Hospital), Kyoung‐Mee Kim(Samsung (South Korea)), Samar Ojaimi(Monash University), Yae‐Jean Kim, Edmund Cheesman(University of Manchester), Lisa Giulino‐Roth(Cornell University), Suranjith L. Seneviratne(Queen's Medical Centre), Ji‐Man Kang(National Cancer Center)
Cited by 103
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k
Gain-of-function human <i>STAT1</i> mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis
|The Journal of Experimental Medicine|2011|797